News - 15 Jul `20Ruxolitinib Cream Might Be An Effective Treatment Of Vitiligo


Researchers investigated the therapeutic potential of Ruxolitinib cream in patients with vitiligo, and it looks very promising.  Results of a 2-year Phase II study at 26 medical centres in 18 states were published in the Lancet just now.  

Ruxolitinib is part of a class of medications called Janus Kinase (JAK) inhibitors. Janus kinases play a significant role in the development of vitiligo, and thus blocking their signaling pathways with the drug can -- hypothetically  -- treat vitiligo. 

Findings from this study suggest that ruxolitinib cream might be an effective treatment option for patients with vitiligo. Once- and twice-daily application at various doses led to significant repigmentation of vitiligo lesions in the face and upper body. The highest response rate was seen with a higher dose, between 24 and 52 weeks of treatment. Some patients got 90% of the color back on the face, yet the majority reported over 50% improvement. The most common treatment-related adverse event was application site pruritus. Approximately 10% of the patients treated with the ruxolitinib cream experienced acne. 

Full approval of the drug is still a ways off, but the outlook is promising. The last Phase 3 clinical trilas for Ruxolitinib cream for vitiligo is scheduled to start at the end of this year.


N.B. Although ruxolitinib is commonly used as an oral treatment for certain blood disorders, for this study it was used topically. The average cost for ruxolitinib oral tablet 5 mg is around $14,390 for a supply of 60 tablets, depending on the U.S. pharmacy you visit. Price is for cash paying customers only, insurance coverage may differ. However, INCYTE offers IncyteCARES Patient Assistance Program for those without prescription coverage and gross family household income at or less than $125,000.